Caplin Point Laboratories Ltd. NSE: CAPLIPOINT | BSE: 524742

Mid-range Performer

Download real time

2056.80 30.70 (1.52%)

28.63% Gain from 52W Low

80,395

NSE+BSE Volume

NSE 10 Oct, 2025 3:31 PM (IST)

Caplin Point Laboratories Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Caplin Point Laboratories Ltd. from all sources in a single place.

Caplin Point Laboratories Ltd.

04 Oct 2025

2056.80

1.52%

Company Update

Caplin Point Laboratories Ltd - 524742 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, …

BSE India

Intimation pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018

Caplin Point Laboratories Ltd.

29 Sep 2025

2056.80

1.52%

SAST

Caplin Point Laboratories Ltd - 524742 - Closure of Trading Window

BSE India

Closure of Trading Window

Caplin Point Laboratories Ltd.

23 Sep 2025

2056.80

1.52%

AGM

Caplin Point Laboratories Ltd - 524742 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report

BSE India

Voting Results and Scrutinizer Report for the 34th Annual General Meeting

Caplin Point Laboratories Ltd.

22 Sep 2025

2056.80

1.52%

Company Update

Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Intimation of Appointment of Secretarial Auditor of the Company

Caplin Point Laboratories Ltd.

22 Sep 2025

2056.80

1.52%

AGM

Caplin Point Laboratories Ltd - 524742 - Shareholder Meeting / Postal Ballot-Outcome of AGM

BSE India

Proceedings of 34th Annual General Meeting of the Company

Caplin Point Laboratories Ltd.

03 Sep 2025

2056.80

1.52%

Caplin Point's unit gets USFDA nod for generic milrinone lactate injection

Business Standard

Pharma firm Caplin Point Laboratories Ltd on Wednesday said its arm Caplin Steriles Ltd has received final approval from the US health regulator for its generic milrinone lactate in 5 per cent dextrose injection indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. The approval granted by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) milrinone lactate in 5 per cent Dextrose Injection of strengths 20 mg/100 mL and 40 mg/200 mL in single-dose infusion bags, Caplin Point Laboratories said in a regulatory filing. The approved injection is a generic therapeutic equivalent version of the reference listed drug PRIMACOR in dextrose 5 per cent, by Sanofi Aventis US LLC, it added. Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure, the company said. Citing IQVIA (IMS Health) data, the company said milrinone lactate in 5 per cent...

Caplin Point Laboratories Ltd. is trading below all available SMAs

Caplin Point Laboratories Ltd.

03 Sep 2025

2056.80

1.52%

Company Update

Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press release - Receipt of USFDA Approval

Caplin Point Laboratories Ltd.

01 Sep 2025

2056.80

1.52%

Company Update

Caplin Point Laboratories Ltd - 524742 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper publication on Notice of 34th Annual General Meeting of the Company along with e-voting information

Caplin Point Laboratories Ltd.

30 Aug 2025

2056.80

1.52%

Corp. Note

Caplin Point Laboratories Ltd - 524742 - Business Responsibility and Sustainability Reporting (BRSR)

BSE India

Business Responsibility and Sustainability Reporting for the Financial Year 2024-25

Caplin Point Laboratories Ltd.

30 Aug 2025

2056.80

1.52%

AGM

Caplin Point Laboratories Ltd - 524742 - Notice Of 34Th Annual General Meeting Of The Company

BSE India

Notice of 34th Annual General Meeting of the Company

Is Caplin Point Laboratories Ltd. worth buying?

485 Votes:

Buy 80.82%

Sell 12.16%

Hold 7.01%

RESEARCH REPORTS

Buy SEE REPORTS >

Buy SEE REPORTS >